Clinical Trial Update: Intratumoral Application of L19IL2 in Patients With Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on intratumoral delivery of L19IL2 in patients with melanoma; the Phase 2 study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• L19IL2 (L19-IL-2)

Snippet

Sponsor: Philogen S.p.A. | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED